A Study to Assess the Safety, and Tolerability of Nivolumab + Relatlimab Fixed-Dose Combination (FDC) In Unresectable or Metastatic Melanoma Participants In India
← catalyst calendarNCT07459543 · readout in 1,011 d
Sponsored by Bristol-Myers Squibb (industry) · BMY — their whole pipeline →.
Phase
Phase 4
Status
Not yet recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
40estimated
Sites
11
Country
India
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-11-15 | estimated | When the study began enrolling |
| Primary completion | 2029-05-26 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2029-05-28 | estimated | The whole study's end, after follow-up |
| First posted | 2026-03-09 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-12 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Unresectable Melanoma
- Metastatic Melanoma
Intervention
- Drug: Nivolumab + Relatlimab — also filed as Relopduo, BMS-986213
Primary outcomes
what the primary-completion date above is the date OFIncidence of adverse events (AEs)
measured Up to 30 weeks
Incidence of drug-related AEs
measured Up to 30 weeks
Incidence of serious adverse events (SAEs)
measured Up to 30 weeks
Incidence of drug-related SAEs
measured Up to 30 weeks
Incidence of immune-mediated adverse events (IMAEs)
measured Up to 30 weeks
AEs leading to discontinuation of treatment
measured Up to 30 weeks
Number of deaths
measured Up to 30 weeks
Number of participants with laboratory abnormalities
measured Up to 30 weeks
Permalink · BMY's whole pipeline · Catalyst calendar · Every registered study · What changed